Opinion|Videos|October 22, 2025

Tailoring Empiric Therapy for Skin and Soft Tissue Infections

Effective empiric therapy requires balancing coverage for common bacteria while considering patient stability, adherence, and potential for chronic or atypical infections.

When choosing empiric therapy for skin and soft tissue infections, clinicians must weigh the likelihood of bacterial pathogens against the possibility of atypical causes. Chronic or refractory infections, especially those presenting with ulcerations or nodularity, often hint at unusual organisms that require more targeted investigation. Recognizing these patterns early helps prevent unnecessary prolonged use of standard antibiotics and improves clinical outcomes.

Empiric antibiotic selection typically covers both common bacterial causes unless the presentation clearly indicates one over the other. Decision-making also hinges on the patient’s comorbidities, clinical stability, and reliability in following treatment plans. For healthy outpatients, oral regimens may suffice, while those with more severe infections or compliance concerns benefit from supervised therapy or long-acting intravenous options. This approach ensures effective bacterial eradication while minimizing hospitalization.

Increasingly, providers emphasize tailored therapy over broad empiricism. Avoiding unnecessary broad-spectrum coverage preserves antibiotic stewardship and prevents resistance. The overall goal is to match treatment intensity to infection severity, patient behavior, and the underlying risk profile, ensuring both clinical success and sustainable antimicrobial practice.

Related to this article

Measles Update: September 25, 2026
The latest CDC numbers show a 5.4% increase of measles cases from week-to-week. This year has already become the worst for the number of measles cases in the US since the disease was declared eliminated in 2000. With the start of respiratory virus season, case numbers are expected to continue to increase significantly.
Asymptomatic C difficile Colonization in Infants Doesn’t Mean Benign
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.